CAR-T Cell Therapy Program

Expertise for cancer immunotherapy

Lymphoma consultation at Mayo Clinic

Mayo Clinic's CAR-T Cell Therapy Program

Mayo Clinic's CAR-T Cell Therapy Program offers a new cancer immunotherapy that involves genetically modifying T cells to activate the immune system to recognize and destroy certain cancers. Chimeric antigen receptor (CAR)-T cell therapy, also known as CAR-T cell therapy, was approved by the Food and Drug Administration in October 2017.

CAR-T cell therapy is not the same as stem cell transplant or chemotherapy. CAR-T cell therapy may be a treatment option for:

  • Relapsed, refractory B-cell acute lymphoblastic leukemia
  • Relapsed, refractory B-cell non-Hodgkin's lymphoma
  • Other types of cancer and medical conditions undergoing clinical studies

The Mayo Clinic CAR-T Cell Therapy Program is one of a few such landmark programs at select medical centers, with experts trained and certified to manage CAR-T cell therapy.

Mayo Clinic was one of the centers that treated people as part of the clinical trial that led to FDA approval of CAR-T cell therapy.

Learn more about CAR-T cell therapy at Mayo Clinic.